Viitteet:

• Arellano FM, Wentworth CE, Arana A, Fernández C, Paul CF. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. Invest Dermatol 127:808-16, 2007
• Beck LA, Leung DYM.  Allergic sensitization through the skin induces systemic allergic responses. J Allergy Clin Immunol 106(suppl):258-63, 2000
• Berth-Jones J, Damstra RJ, Golsch S, Livden JK, Van Hooteghem O, Allegra F, Parker CA. Multinational Study Group. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk for relapse in atopic dermatitis: randomised, double blind, parallel group study. BMJ 326:1367-72, 2003
• Berth-Jones J, Graham-Brown RA, Marks R, Camp RD, English JS, Freeman K, et al. Long-term efficacy and safety of cyclosporine in severe adult atopic dermatitis. Br J Dermatol 136:76.81, 1997
• Berth-Jones J, Takwale A, Tan E, Barclay G, Agarwal S, Ahmed I, et al. Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial. Br J Dermatol 147:324-30, 2002
• Breneman D, Fleischer AB Jr, Abramovits W, Zeichner J, Gold MH, Kirsner RS, Shull TF, Crowe AW, Jaracz E, Hanifin JM; Tacrolimus Ointment Study Group. Intermittent therapy for flare prevention and long-term disease control in stabilized atopic dermatitis: a randomized comparison of 3-times-weekly applications of tacrolimus ointment versus vehicle. J Am Acad Dermatol 58:990-9, 2008
• Callen J, Chamlin S, Eichenfield LF, Ellis C, Girardi M, Goldfarb M, Hanifin J, Lee P, Margolis D, Paller AS, Piacquadio D, Peterson W, Kaulback K, Fennerty M, Wintroub BU. A systematic review of the safety of topical therapies for atopic dermatitis. Br J Dermatoloy 156:203-21, 2007
• Chamlin SL, Kao J, Frieden IJ, Sheu MY, Fowler AJ, Fluhr JW, Williams ML, Elias PM. Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: changes in barrier function provide a sensitive indicator of disease activity. J Am Acad Dermatol 47:198-208, 2002
• Cork MJ, Robinson DA, Vasilopoulos Y, Ferguson A, Moustafa M, MacGowan A, et al. New perspectives in epidermal barrier dysfunction in atopic dermatitis: Gene-environment interactions. J Allergy Clin Immunol 118:3-21, 2006
• Faergemann J, Christensen O, Sjovall P, Johnsson A, Hersle K, Nordin P, Edmar B, Svensson A. An open study of efficacy and safety of long-term treatment with mometasone furoate fatty cream in the treatment of adult patients with atopic dermatitis. J Eur Acad Derm Venereol 14:393-6, 2000
• Forman S, Garrett A. Success of omalizumab as monotherapy in adult atopic dermatitis: case report and discussion on the high-affinity immunoglobulin E receptor, Fcepsilon RI. Cutis 80:38-40, 2007
• Glazenburg EJ, Wolkerstorfer A, Gerretsen AL, Mulder PG, Oranje AP. Efficacy and safety of fluticasone propionate 0.005% ointment in the long-term maintenance treatment of children with atopic dermatitis: Differences between boys and girls? Pediatr Allergy Immunol. 2008 Feb 22. Epub ahead of print.
• Granlund H, Erkko P, Sinisalo M, Reitamo S. Cyclosporin A in atopic dermatitis: time to relapse and effect of intermittent therapy. Br J Dermatol 132:106-12, 1995
• Granlund H, Remitz A, Kyllönen H, Lauerma AI, Reitamo S. Treatment of lichenified atopic eczema with topical tacrolimus. Acta Derm Venereol 81:314-5, 2001
• Hanifin J, Gupta AK, Rajagopalan R. Intermittent dosing of fluticasone propionate cream for reducing the risk for relapse in atopic dermatitis patients. Br J Dermatol 147:528-37, 2002
• Hanifin JM, Paller AS, Eichenfield L, Clark RA, Korman N, Weinstein G, Caro I, Jaracz E, Rico MJ. US Tacrolimus Ointment Study Group. Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis. J Am Acad Dermatol 53(suppl):186-94, 2005
• Harper JI, Ahmed I, Barclay G, Lacour M, Hoeger P, Cork MJ, et al. Cyclosporin for severe childhood atopic dermatitis: Short course versus continuous therapy. Br J Dermatol 142:52-8, 2000Hebert AA. Review of pimecrolimus cream 1% for the treatment of mild to moderate atopic dermatitis. Clin Ther 28:1972-82, 2006
• Hoare C, Li Wan Po A, Williams H. Systematic review of treatments of atopic dermatitis. Health Technol Assess 4 (37), 2000
• Hughes J, Rustin M. Corticosteroids. Clin Dermatol 15:715-21, 1997Hughes R, Collins P, Rogers S. Further experience of using azathioprine in the treatment of severe atopic dermatitis. Clin Exp Dermatol 33:710-1, 2008
• Jacobi A, Antoni C, Manger B, Schuler G, Hertl M. Infliximab in the treatment of moderate-to-severe atopic dermatitis. J Am Acad Dermatol 52:522-6, 2005
• Kapp A, Papp K, Bingham A, Folster-Holst R, Ortonne JP, Potter PC, Gulliver W, Paul C, Molloy S, Barbier N, Thurston M, de Prost Y. Flare Reduction in Eczema with Elidel (infants) multicenter investigator study group. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J Allergy Clin Immunol 110:277-84, 2002
• Kyllönen H, Remitz A, Mandelin JM, Elg P, Reitamo S. Effect of one-year intermittent treatment with topical tacrolimus monotherapy on skin collagen synthesis in patients with atopic dermatitis. Br J Dermatol 150:1174-1181, 2004   
• Luger TA, Lahfa M, Folster-Holst R, Gulliver WP, Allen R, Molloy S, Barbier N, Paul C, Bos JD. Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate-to-severe atopic dermatitis. J Dermatol Treat 15:169-78, 2004
• Margolis DJ, Hoffstad O, Bilker W. Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults. Dermatology 214:289-95, 2007
• Meduri NB, Vandergriff T, Rasmussen H, Jacobe H. Phototherapy in the management of atopic dermatitis: a systematic review. Photodermatol Photoimmunol Photomed  23:106-12, 2007
• Meggitt SJ, Gray JC, Reynolds NJ. Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomized controlled trial. Lancet 367:839-46, 2006
• Meurer M, Fartasch M, Albrecht G, Vogt T, Worm M, Ruzicka T, Altmeyer PJ, Schneider D, Weidinger G, Braeutigam M. CASM-DE-01 Study Group. Long-term efficacy and safety of pimecrolimus cream 1% in adults with moderate atopic dermatitis. Dermatology. 208:365-72, 2004
• Murray ML, Cohen JB. Mycophenolate mofetil therapy for moderate-to-severe atopic dermatitis. Clin Exp Dermatol 32:23-7, 2007
• Neumann E, Amtage D, Bruckner-Tuderman L, Mockenhaupt M. A single-center open-label long-term comparison of tacrolimus ointment and topical corticosteroids for treatment of atopic dermatitis.  J Dtsch Dermatol Ges 6:548-53, 2008
• Oldhoff J, Darsow U, Werfel T, Katzer K, Wulf A, Laifaoui J, Hijnen D, Plötz S, Knol E, Kapp A, Bruijnzeel-Koomen C, Ring J, Bruin-Weller M. Anti-IL-5 recombinant humanized monoclonal antibody (Mepolizumab) for the treatment of atopic dermatitis. Allergy 60:693-6, 2005
• Paller AS, Eichenfield LF, Kirsner RS, Shull T, Jaracz E, Simpson EL; for the US Tacrolimus Ointment Study Group. Three Times Weekly Tacrolimus Ointment Reduces Relapse in Stabilized Atopic Dermatitis: A New Paradigm for Use. Pediatrics 122:1210-8, 2008
• Paller AS, Lebwohl M, Fleischer AB Jr, Antaya R, Langley RG, Kirsner RS, Blum RR, Rico MJ, Jaracz E, Crowe A, Linowski GJ. US/Canada Tacrolimus Ointment Study Group. Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies. J Am Acad Dermatol 52:810-22, 2005
• Papp K, Werfel T, Folster-Holst R, Ortonne JP, Potter PC, de Prost Y, Davidson MJ, Barbier N, Goertz HP, Paul C. Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year study. J Am Acad Dermatol 52:240-6, 2005
• Patel TS, Greer SC, Skinner RB Jr. Cancer concerns with topical immunomodulators in atopic dermatitis: overview of data and recommendations to clinicians. Am J Clin Dermatol 8:189-94, 2007
• Peserico A, Städtler G, Sebastian M, Fernandez RS, Vick K, Bieber T. Reduction of relapses of atopic dermatitis with methylprednisolone aceponate cream twice weekly in addition to maintenance treatment with emollient: a multicentre, randomized, double-blind, controlled study. Br J Dermatol, 158:801-7, 2008
• Reitamo S, Ortonne JP, Sand C, Cambazard F, Bieber T, Folster-Holst R, Vena G, Bos JD, Fabbri P, Groenhoej Larsen C, European Tacrolimus Ointment Study Group. A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate-to-severe atopic dermatitis. Br J Dermatol 152:1282-9, 2005
• Reitamo S, Remitz A, Kyllönen H, Saarikko J. Topical noncorticosteroid immunomodulation in the treatment of atopic dermatitis. Am J Clin Dermatol 3:381-8, 2002
• Reitamo S, Rustin M, Harper J, Kalimo K, Rubins A, Cambazard F, Brenninkmeijer EE, Smith C, Berth-Jones J, Ruzicka T, Sharpe G, Taieb A; 0.1% Tacrolimus Ointment Long-term Follow-up Study Group. A 4-year follow-up study of atopic dermatitis therapy with 0.1% tacrolimus ointment in children and adult patients. Br J Dermatol 159:942-51, 2008
• Remitz A, Harper J, Rustin M, Goldschmidt WF, Palatsi R, van der Valk PG, Sharpe G, Smith CH, Dobozy A, Turjanmaa K; European Tacrolimus Ointment Study Group. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. Acta Derm Venereol 87:54-61, 2007
• Remitz A, Harper J, Rustin M, Goldschmidt WF, Palatsi R, van der Valk PG, Sharpe G, Smith CH, Dobozy A, Turjanmaa K. European Tacrolimus Ointment Study Group. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. Acta Derm Venereol 87:54-61, 2007
• Remitz A, Kyllönen H, Granlund H, Reitamo S: Tacrolimus ointment reduces staphylococcal colonization of atopic dermatitis lesions. J Allergy Clin Immunol 107:196-197, 2001
• Rubins N, Gutmane G, Valdmane N, Stevenson P, Foster C, Undre N. Pharmacokinetics of 0.1% tacrolimus ointment after first and repeated application to adults with moderate-to-severe atopic dermatitis. J Invest Dermatol 125:68-71, 2005
• Rustin MH. The safety of tacrolimus ointment for the treatment of atopic dermatitis: a review. Br J Dermatol 157:861-73, 2007
• Schmitt J, Schäkel K, Schmitt N, Meurer M. Systemic treatment of severe atopic dermatitis: A systematic review. Acta Derm Venereol 87:100-11, 2007
• Silverberg NB, Paller AS. Leukotriene receptor antagonists are ineffective for severe atopic dermatitis. J Am Acad Dermatol 50:485-6, 2004
• Spergel J, Mizoguchi E, Brewer J, Martin T, Bhan A, Geha R. Epicutaneous sensitization with protein antigen induces localized allergic dermatitis and hyper-responsiveness to methacoline after single exposure to aerosolized antigen in mice. J Clin Invest 101:1614-22, 1998
• Spergel J, Paller A. Atopic dermatitis and the atopic march. J Allergy Clin Immunol 112(suppl):118-27, 2003
• Thaçi D, Reitamo S, Gonzalez Ensenat MA, Moss C, Boccaletti V, Cainelli T, van der Valk P, Buckova H, Sebastian M, Schuttelaar ML, Ruzicka T; for the European Tacrolimus Ointment Study Group. Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study. Br J Dermatol 159:1348-56, 2008
• Vickery BP. Skin barrier function in atopic dermatitis. Curr Opin Pediatr 19:89-93, 2007
• Virtanen H, Kari O, Kari M, Reitamo S. Tacrolimus ointment in the treatment of atopic blepharoconjuntivitis. A retrospective study. Acta Ophth Scand. 84:693-5, 2006
• Virtanen H, Remitz A, Malmberg P, Rytilä P, Metso T, Haahtela T, Reitamo S. Topical tacrolimus for atopic dermatitis - does it benefit the airways? A four-year follow-up. J Allergy Clin Immunol 120:1464-6, 2007
• Weatherhead SC, Wahie S, Reynolds NJ, Meggitt SJ. An open-label, dose-ranging study of methotrexate for moderate-to-severe adult atopic eczema. Br J Dermatol 156:346-51, 2007
• Weidinger S, Rodriguez  E, Stahl C, Wagenpheil S, Klopp N, Illig T, Novak N. Filaggrin mutations strongly predispose to early-onset and extrinsic atopic dermatitis. J Invest Dermatol 127:724-6, 2007
• Werfel T, Breuer K, Ruéff F, Przybilla B, Worm M, Grewe M, Ruzicka T, Brehler R, Wolf H, Schnitker J, Kapp A. Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-response study. Allergy 61:202-5, 2006
• Wollenberg A, Reitamo S, Girolomoni G, Lahfa M, Ruzicka T, Healy E, Giannetti A, Bieber T, Vyas J, Deleuran M; European Tacrolimus Ointment Study Group. Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. Allergy 63:742-50, 2008
• Wollenberg A, Sidhu MK, Odeyemi I, Dorsch B, Koehne-Volland R, Schaff M, Ehlken B, Berger K. Economic evaluation of maintenance treatment with tacrolimus 0.1% ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol 159:1322-30, 2008
• Xhauflaire-Uhoda E, Thirion L, Piérard-Franchimont C, Piérard GE. Comparative effect of tacrolimus and betamethasone valerate on the passive sustainable hydration of the stratum corneum in atopic dermatitis. Dermatology 214:328-32, 2007
• Zonneveld IM, De Rie MA, Beljaards RC, Van-Der-Rhee HJ, Wuite J. Zeegelaar J, et al. The long-term safety and efficacy of cyclosporine in severe refractory atopic dermatitis: a comparison of two dosage regimens. Br J Dermatol 135(suppl):15-20, 1996